Waltham, Massachusetts – (The Hosting News) – October 17, 2006 – Web host and data management solutions firm, Phase Forward, will release financial results for the quarter ended September 30, 2006 and hold a conference call with investors hosted by Bob Weiler, President and Chief Executive Officer, and Rodger Weismann, Senior Vice President and Chief Financial Officer.
The investor conference call,
will discuss its third quarter financial results and its outlook for the final quarter of 2006. The call will be held on Wednesday, October 25, 2006
at 5:00 p.m. (EST). The investor conference call will be available via live web cast on the CompanyÃ¢â‚¬â„¢s web site under the ”Investors” tab. To participate by telephone, the domestic dial-in number is 800.260.8140 and the international dial-in is +1 617.614.3672. The access code is 87855941. Investors are advised to dial-in at least five minutes prior to the call to register. The web cast will be available for replay until November 24, 2006.
Recently, Phase Forward reported that revenues for the second quarter of 2006 were $24.7 million, a 19% increase from $20.7 million in the second quarter of 2005. Within total revenue, InForm license, application hosting and other related revenues were $16.3 million, an increase of 19% from $13.7 million in the prior year period.
Phase Forward is a provider of integrated data management solutions for clinical trials and drug safety. The company offers solutions for electronic data capture (InForm), clinical data management (Clintrial), clinical trials signal detection (CTSD), strategic pharmacovigilance (WebVDME) and Signal Management), adverse event reporting (Clintrace) and applied data standards (WebSDM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards.
Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 230 organizations and regulatory agencies worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Guidant, Merck, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter and Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute and Serono.
To learn more, please visit: www.phaseforward.com.